CORAL GABLES, FL / ACCESSWIRE / February 1, 2019 / The healthcare stock market's success is largely dependent on the fact that, as the global population increases, more people will fall prey to illnesses and ailments, and in turn, these individuals will need access to qualitative, effective medical treatment. With the advent of new approaches to medical care, as well as innovative medical technologies coming out of the healthcare industry, news surrounding innovative companies putting their skills to the test in the has worked to attract investors looking for potential opportunities in the space. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Titan Pharmaceuticals Inc (TTNP), Aileron Therapeutics Inc (ALRN), Enochian Biosciences Inc (ENOB) represent four healthcare stocks setting the pace on Friday afternoon.
Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing nuanced approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network.
The Company has seen impressive gains over the last few months as a result of momentum gained from several key strategic investments meant to showcase to the industry that Premier not only believes in the future of healthcare, but is determined to put in place corporate strategies meant to advance these goals, and provide for consumers looking for primary care.
Premier Health Group (OTC:PHGRF) (CSE:PHGI) announced earlier this week that, further to its news release dated January 10, 2019, the Company has acquired all outstanding securities of Cloud Practice Inc. As a result of the acquisition, Cloud Practice's Founders, including CEO Jordan Visco, and entire support team, consisting of several software developers and sales staff, will join and work alongside the Premier Health team to offer tools and resources providing for better efficiency on a day-to-day basis for both physicians and customers.
Per the official details of the agreement, Premier will pay to the Cloud Practice shareholders total consideration of up to $5 million, $2 million dollars in cash to be paid out as follows: (i) $500,000 paid in cash on signing of the binding LOI as a refundable deposit, (ii) $500,000 in cash payable on closing, (iii) $500,000 in cash payable 90 days after closing, (iv) $500,000 in cash payable within six months of the LOI subject to the satisfaction of certain milestones related to the integration of the Juno EMR, and $3 million payable in common shares of Premier at a deemed price of $0.76 per share.
Dr. Essam Hamza, CEO of Premier Health Group (OTC:PHGRF) (CSE:PHGI), commented, "we are very excited to have completed this acquisition and to have the experienced team at Cloud Practice join the team at Premier Health. With this acquisition, we now have a medical software company with national reach. Thus, enabling us to build on our patient-centric technology platform that will integrate telemedicine, online booking, and other premium services with our electronic medical records (EMR) system."
Titan Pharmaceuticals Inc (TTNP) announced earlier this week updates on their recent U.S. commercial relaunch of Probuphine implant, the Company's unique six-month treatment for opioid use disorder.
In a press release regarding the Company's updates, Dane Hallberg, Chief Commercial Officer for Titan, said, "we are pleased that the initial stages of our relaunch have shown that the current market is highly receptive to our market segmentation strategy and core messaging. Along with the positive feedback we have received from both health care providers and their patients, the increase in product shipments suggests that our relaunch strategy is sound, and we look forward to updating investors as this initiative progresses."
Aileron Therapeutics Inc (ALRN), a leader in the field of stabilized, cell-permeating peptides used to treat cancer and other diseases, announced earlier this month that they had enrolled their first patient in a Phase 2a expansion cohort intended to assess preliminary activity and safety of ALRN-6924 in combination with Pfizer's palbociclib, also known as IBRANCE®, in cancer patients with MDM2-amplified solid tumors.
Vojo Vukovic, Chief Medical Officer of Aileron, commented, "we are excited to launch this Phase 2a expansion cohort, expanding on our ALRN-6924 clinical trial combination program. ALRN-6924 and palbociclib address the MDM2 (p53) and CDK4 (Rb) pathways, which have interdependent roles in cancer biology, and preclinical results recently presented by Aileron show synergistic activity for ALRN-6924 and palbociclib in cancer cells and animal models."
Enochian Biosciences Inc (ENOB) saw impressive gains in mid-afternoon trading on Friday, with shares up 11.88%, trading at $7.25 per share. The Company, which focuses on the development and commercialization of novel therapies for HIV/AIDS and oncology, announced earlier this month that the Company's new Executive Vice-Chair, Dr. Mark Dybul would be taking over the leadership of the Company following the departure of Eric Leire as Chief Executive Officer.
Rene Sindlev, Chair of Enochian's Board of Directors, commented, "Enochian would like to congratulate Mark on his new position as Executive Vice-Chair. Mark has extensive experience in managing larger teams within growing organizations, and will be a key factor in building our organization and managing the clinical and regulatory processes in commercializing our existing science in both HIV/AIDS and oncology."
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.
Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 ( CASH) for & were paid "500,000" shares of restricted common shares (as of 1/2/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
View source version on accesswire.com: